Table I.
Descriptive statistics; P by Rank Sum or Fisher’s exact test
|
Mean or Weighted Frequency (SE)
|
P | ||
|---|---|---|---|
| Amputation (n = 29) | Control (n = 20) | ||
| Age | 70.7 years (±2.7) | 63.5 years (±2.2) | 0.029 |
| Race: | 0.596 | ||
| White | 16 (55.17%) | 14 (70.00%) | |
| Black | 8 (27.59%) | 4 (20.00%) | |
| Hispanic | 5 (17.24%) | 2 (10.00%) | |
| Female | 9 (31.03%) | 11 (55.00%) | 0.140 |
| BMI | 24.7 kg/m2 (±1.2) | 34.2 kg/m2 (±1.8) | <0.0001 |
| Diabetes Mellitus | 19 (65.52%) | 5 (25.00%) | 0.006 |
| Hypertension | 27 (93.10%) | 15 (75.00%) | 0.087 |
| Hyperlipidemia | 20 (68.97%) | 10 (50.00%) | 0.149 |
| CAD | 17 (58.62%) | 3 (15.00%) | 0.002 |
| CHF | 7 (24.14%) | 0 (0.00%) | 0.018 |
| CVA | 8 (27.59%) | 0 (0.00%) | 0.010 |
| Renal Disease | 12 (41.38%) | 0 (0.00%) | 0.001 |
| Pulmonary Disease | 9 (31.03%) | 0 (0.00%) | 0.005 |
| Smoking History | 18 (62.07%) | 5 (25.00%) | 0.006 |
| Antiplatelet Therapy | 22 (75.86%) | 14 (70.00%) | 0.446 |
| Warfarin | 9 (27.58%) | 11 (55.00%) | 0.051 |
| Calcium Channel Blocker | 10 (34.48%) | 1 (5.00%) | 0.015 |
| Beta Blocker | 24 (82.76%) | 3 (15.00%) | <0.0001 |
| ACE Inhibitor/ARB | 12 (41.38%) | 12 (60.00%) | 0.161 |
| Statin | 22 (75.87%) | 9 (45.00%) | 0.029 |
| Insulin | 18 (62.07%) | 3 (15.00%) | 0.001 |
| NSAID | 23 (79.31%) | 17 (85%) | 0.455 |
| Steroid | 3 (10.34%) | 0 (0.00%) | 0.198 |